Gilead Sciences Presents New 5-Year Data Reinforcing Biktarvy As Long-Term HIV Treatment; Investigational Dosing Frequencies Aim To Expand Options And Address Unmet Needs; Key Findings Presented At AIDS 2024 Conference Highlight Innovative HIV Treatment Portfolio And Research Pipeline

7/25/24 9:16:38 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $GILD alert in real time by email

Get the next $GILD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GILD

Date	Price Target	Rating	Analyst
11/15/2024	$110.00	Outperform	Wolfe Research
11/14/2024	$125.00	Buy	Citigroup
11/8/2024		Buy → Hold	Maxim Group
10/21/2024	$74.00 → $96.00	Market Perform → Outperform	Leerink Partners
10/17/2024	$105.00	Outperform	Bernstein
10/7/2024	$78.00 → $100.00	Equal Weight → Overweight	Wells Fargo
7/8/2024	$93.00	Mkt Perform → Outperform	Raymond James
5/1/2024	$90.00 → $85.00	Buy	Maxim Group

More analyst ratings

$GILD
Press Releases

Fastest customizable press release news feed in the world

Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
– New Findings Demonstrate 81% of Participants Achieve Durable Biochemical Response by Month 30 with Livdelzi – – Nearly Half of Participants with Primary Biliary Cholangitis (PBC) Achieve Alkaline Phosphatase (ALP) Normalization with Livdelzi – – Livdelzi Reduced Pruritus Severity in PBC Participants and Led to Near Resolution of Itch in 27% of Participants with Moderate to Severe Itch – Gilead Sciences, Inc. (NASDAQ:GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi® (seladelpar) achieved a composite biochemical
11/15/24 11:00:00 AM ET
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Gilead Prices $3.5 Billion of Senior Unsecured Notes
Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of $750 million of 4.80% senior notes maturing in 2029, $1 billion of 5.10% senior notes maturing in 2035, $1 billion of 5.50% senior notes maturing in 2054 and $750 million of 5.60% senior notes maturing in 2064. The offering is expected to close November 20, 2024, subject to customary closing conditions. Gilead intends to use the net proceeds from this offering for general corpor
11/13/24 8:24:00 PM ET
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Gilead Sciences to Present at Upcoming Investor Engagements
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthcare Conference on Wednesday, November 20 at 9:30 AM Greenwich Mean Time Piper Sandler Annual Healthcare Conference on Tuesday, December 3 at 11:00 AM Eastern Time Annual Evercore ISI HealthCONx Conference on Wednesday, December 4 at 11:40 AM Eastern Time The live webcasts can be accessed at the company's investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakth
11/8/24 4:05:00 PM ET
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$GILD
Financials

Live finance-specific insights

Gilead Sciences Announces Third Quarter 2024 Financial Results
Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% Year-Over-Year to $816 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its third quarter 2024 results of operations. "Gilead's third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy. Based on this very strong topline growth and disciplined operating expense management, we are increasing our full year revenue, operating income, and earnings per share guidance," said Daniel O'Day, Gilead's Chairman and Chief Executive Offic
11/6/24 4:02:00 PM ET
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all peop
10/9/24 4:05:00 PM ET
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Gilead Sciences Announces Second Quarter 2024 Financial Results
Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.7 billion Biktarvy Sales Increased 8% Year-Over-Year to $3.2 billion Oncology Sales Increased 15% Year-Over-Year to $841 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its second quarter 2024 results of operations. "Gilead has had another strong quarter with 6% year-over-year growth in our base business. This was driven by sales of our therapies for HIV, Oncology and Liver Disease, including 8% growth for Biktarvy," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "One of the key highlights of the quarter was interim data from the Phase 3 PURPOSE 1 trial showing 100% efficacy for lenacapa
8/8/24 4:02:00 PM ET
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa
6/15/23 4:01:00 PM ET
$GILD
$GLPG
$JNJ
$LIVN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Gilead Appoints Cindy Perettie Executive Vice President of Kite
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead's senior leadership team, effective May 30. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005214/en/Gilead Appoints Cindy Perettie Executive Vice President of Kite (Photo: Business Wire) Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care. Most recently, she was Head of Roche's Molecular Lab Solutions where she oversaw the PCR (polymerase chain reactio
5/16/23 4:01:00 PM ET
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors
MONTREAL, Nov. 29, 2022 /PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Melissa Koomey to its Board of Directors. Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers. "We are excited to have Melissa join the Thryv Board of Directors at this pivotal time in our story. Our lead compound will emerge from initial safety studies early in 2023 and we will accelerate into efficacy trials with Melissa's experience and insights in Long QT Syndrome," said Paul F. Truex, Thryv's
11/29/22 8:00:00 AM ET
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Gilead Sciences Presents New 5-Year Data Reinforcing Biktarvy As Long-Term HIV Treatment; Investigational Dosing Frequencies Aim To Expand Options And Address Unmet Needs; Key Findings Presented At AIDS 2024 Conference Highlight Innovative HIV Treatment Portfolio And Research Pipeline

Chat with this insight

Recent Analyst Ratings for $GILD

$GILD Press Releases

Fastest customizable press release news feed in the world

Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Prices $3.5 Billion of Senior Unsecured Notes

Gilead Sciences to Present at Upcoming Investor Engagements

$GILD Market Insights

Live Market Insights

This Is What Whales Are Betting On Gilead Sciences

Gilead Sciences shares are trading higher after the company announced new 5-year data reinforcing Biktarvy as a long term HIV treatment.

Gilead Sciences Presents New 5-Year Data Reinforcing Biktarvy As Long-Term HIV Treatment; Investigational Dosing Frequencies Aim To Expand Options And Address Unmet Needs; Key Findings Presented At AIDS 2024 Conference Highlight Innovative HIV Treatment Portfolio And Research Pipeline

$GILD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer Mercier Johanna sold $456,400 worth of shares (5,000 units at $91.28), decreasing direct ownership by 6% to 73,127 units (SEC Form 4)

Chief Medical Officer Parsey Merdad exercised 25,000 shares at a strike of $57.92 and sold $2,341,485 worth of shares (25,590 units at $91.50), decreasing direct ownership by 0.59% to 99,599 units (SEC Form 4)

EVP, Corporate Affairs & GC Telman Deborah H converted options into 514 shares and covered exercise/tax liability with 242 shares, increasing direct ownership by 1% to 20,979 units (SEC Form 4)

$GILD SEC Filings

$GILD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

Gilead Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

SEC Form 424B5 filed by Gilead Sciences Inc.

SEC Form FWP filed by Gilead Sciences Inc.

FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC

$GILD Financials

Live finance-specific insights

Gilead Sciences Announces Third Quarter 2024 Financial Results

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

Gilead Sciences Announces Second Quarter 2024 Financial Results

$GILD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wolfe Research initiated coverage on Gilead Sciences with a new price target

Citigroup initiated coverage on Gilead Sciences with a new price target

Gilead Sciences downgraded by Maxim Group

$GILD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

$GILD Leadership Updates

Live Leadership Updates

$GILD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

Gilead Appoints Cindy Perettie Executive Vice President of Kite

Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors

SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

SEC Form SC 13G filed by Gilead Sciences Inc.

Recent Analyst Ratings for
$GILD

$GILD
Press Releases

$GILD
Market Insights

$GILD
Insider Trading

$GILD
SEC Filings

$GILD
FDA approvals

$GILD
Financials

$GILD
Analyst Ratings

$GILD
Insider Purchases

$GILD
Leadership Updates

$GILD
Large Ownership Changes